ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

8:30AM-10:30AM: Abstract Number: 0999

UVB-irradiated Keratinocyte-derived Extracellular Vesicles Induced Proinflammatory Responses in Macrophages

Innate Immunity Poster (0992–1006)

8:30AM-10:30AM: Abstract Number: 1115

Uveitis and Inflammatory Bowel Disease: Study of 1449 Patients from a Single University Center

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

8:30AM-10:30AM: Abstract Number: 1324

Uveitis in 301 Patients with Axial Spondyloarthritis of a Single University Center: Epidemiology, Clinical Features and Biological Treatment

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1323

Uveitis in 406 Patients with Psoriatic Arthritis: Epidemiology, Clinical Characteristics and Relationship with Biological Treatment. Study of a Single University Center

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1321

Uveitis in Patients with Psoriatic Arthritis – a Database Analysis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1307

Uveitis in Spondyloarthritis Patients. Is There Any Specific Clinical Picture?

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1399

Validation of a Giant Cell Arteritis Probability Score

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

8:30AM-10:30AM: Abstract Number: 1290

Validation of a Novel Lupus Multivariable Outcome Score as an Outcome Measure for Systemtic Lupus Erythematosus Trials

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1011

Validation of Bioinformatics Pipeline to Detect NEMO-Deleted Exon 5 Autoinflammatory Syndrome (NEMO-NDAS) and Preliminary Clinical and Immunologic Characterization

Pediatric Rheumatology – Basic Science Poster (1007–1013)

8:30AM-10:30AM: Abstract Number: 1113

Validation of the 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease in a Latin American Cohort

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

8:30AM-10:30AM: Abstract Number: 1332

Validation of the PROMIS-29 Profile in Patients with Active Psoriatic Arthritis Using Data from a Phase 3, Randomized, Placebo-Controlled Study Evaluating Guselkumab (TREMFYA®)

Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

8:30AM-10:30AM: Abstract Number: 1051

Variance of Joint Space Width Across the Tibiofemoral Joint on Knee Radiographs: A Novel Measure of Structure and Progression

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1037

Variations in Total Knee Replacement Utilization and Outcomes in USA and Canada: The Role of Geography and Socioeconomic Factors

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1007

Vascular Deposition of Oxidized LDL Is Increased in Children with Untreated Juvenile Dermatomyositis

Pediatric Rheumatology – Basic Science Poster (1007–1013)

8:30AM-10:30AM: Abstract Number: 1394

Vascular Ultrasound for Giant Cell Arteritis: An Effective Diagnostic Modality for a Fast Track Clinic in the United States

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].